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Aim: To study the differential expression of PKD1 and PKD2 in primary gastric cancer samples and to examine the role of PKD1 and 
PKD2 protein kinases in regulation of gastric tumor cell biology in the model system. Methods: Tumor samples of different histological 
variants of primary gastric cancer were analyzed. PKD1 and PKD2 expression levels in tumor samples were accessed by Western 
blot analysis and quantitative polymerase chain reaction (Q-PCR). As a model system we have used gastric adenocarcinoma сell 
line AGS sublines constitutively transfected by pcDNA3.1 coding PKD1 or PKD2, or empty pcDNA3.1 vector. These cell lines 
were analyzed by Western blot, Q-PCR, MTT and proliferation assays, in vitro scratch and Transwell assays, clonogenic assay. 
Results: It was found that primary gastric tumors possess different levels of PKD1 and PKD2 expression on mRNA and protein 
levels. Low level of PKD1 expression on protein and mRNA level was detected in low differentiated adenocarcinoma and ring cell 
gastric cancer — disorders with poor clinical prognosis. The high level of PKD2 expression was also found in gastric tumors with 
poor prognosis: low differentiated adenocarcinoma and adenogen cancer. To find out whether differential expression of PKD1 and 
PKD2 could affect biology of gastric tumor cells in vitro, we used a model system based on AGS cell line that constitutively expressed 
PKD1 or overexpressed PKD2. PKD1 transfection led to the inhibition of cell proliferation, migration and colony formation, in the 
meanwhile, the PKD2 overexpression enhanced proliferation, migration and colony formation capacities of AGS cells. Conclusions: 
Our data suggest that both downregulation of PKD1 or upregulation of PKD2 expression may determine the behavior of gastric 
tumor cells, which promotes invasive phenotype and could result in general poor prognosis.
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Kinases of protein kinase D (PKD) family are ex-
pressed ubiquitously in different human tissues. PKDs 
could be activated by growth factors, antigen stimula-
tion and oxidative stress, the processes that usually are 
observed during tumor progression [1]. PKDs regulate 
cell-cell contacts by affecting cell adhesion [2, 3]. 
These kinases are involved in the regulation of cell 
proliferation and apoptosis and also participate in epi-
genetic regulation of gene expression. The presence 
of the nuclear translocation signal peptide may allow 
PKD translocation to the nucleus and phosphorylation 
of its nuclear targets, such as transcription factor NF-
kB, histone deacetylases and histone chaperone SET 
[4–6]. Depending on PKD localization site, this kinase 
can be implicated in the regulation of a variety of cel-
lular and subcellular processes, such as Golgi function 
and organization, receptor signalling, apoptotic or an-
tiapoptotic signalling, tumor cell invasion. PKD family 
of protein kinases can be involved in the regulation 
of tumor cells survival [7–9]. Nevertheless, the role 
of different PKD isoforms in these processes in normal 
and malignant cells is not fully clarified. Recently the 
differential expression of PKD genes was found in pri-
mary tumors of different histogenesis: gastric cancer, 
breast cancer, prostate cancer, lymphoproliferative 
disorders [2, 10–13]. Thus, the studies of differen-
tial expression and activity of PKD1 and PKD2 in the 
context of tumor invasiveness and prognosis could 
be of interest for translational research in oncology.
MATERIALS AND METHODS
The protein levels of PKD1 and PKD2 were evalu-
ated in 38 primary tumor samples and surrounding 
tissues from various histological variants of gastric 
cancer that are characterized by different prognosis. 
Samples have been received from the patients cured 
in Kyiv City Oncological Hospital (Kyiv, Ukraine), and 
written consent was obtained from each patient 
before enrolling into the study. The study was ap-
proved by Ethical Committee of R.E.Kavetsky Institute 
of Experimental Pathology, Oncology and Radiobi-
ology, NAS of Ukraine. To access the protein level 
of PKD1/2 we used Western blot analysis [13]. For 
Western blot analysis we used anti-PKCμ rabbit anti-
body that detects both PKD1 and PKD2 (Clone D-20, 
Santa Cruz, USA) and anti-actin rabbit antibody (Santa 
Cruz, USA), secondary goat anti-rabbit antibody con-
jugated with peroxidase (Santa Cruz, USA).
mRNA level of PKD1 and PKD2 kinases was evalu-
ated for 28 tumor samples of gastric cancer by quanti-
tative polymerase chain reaction (Q-PCR). For Q-PCR 
analysis we used Applied Biosystems 7500 System 
SDS (USA). RNA from gastric tissue samples was 
isolated using Tri Reagent (Sigma, USA). RNA were re-
verse transcribed using an M-MLV Reverse Transcrip-
tase and Ribonuclease Inhibitor RNaseOUTTM (Invit-
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rogen, USA) and oligo(dT)18 primer (Fermentas, USA). 
Genetic changes and expression level were analyzed 
by Q-PCR with SYBR Green (Fermentas, USA). Gene 
expression ratios were normalized using a housekeep-
ing gene β2-microglobulin. Following primers were used 
for PKD1: forward — AATGAATGAGGAGGGTAGGG, 
reverse — GCTAGGTGCATTGTCTTGAG; for PKD2: 
forward — TGTGTCCCATTGGTGTTGTC, reverse — 
TTTTATTCCCTACCCTCCTC; for β2-microglobulin: for-
ward — CCGTGTGAACCATGTGACTTTGTC, reverse — 
TGCGGCATCTTCAAACCTCCATGATG. Relative quan-
tification of the obtained results was performed using 
2-∆∆Ct method [14]. Gene expression ratios for tumor 
samples were compared with PKD1 and PKD2 mRNA 
expression level in the signet-ring cell gastric carci-
noma sample, which was chosen because of the lowest 
PKD1 and PKD2 expression levels among all analyzed 
gastric tumor samples. Gene expression ratios for trans-
fected cells were compared with parental cell line AGS. 
For in vitro studies the gastric adenocarcinoma 
cell line AGS was used. Cells were cultivated in IMDM 
media (Sigma, USA) supplemented with 10% of fetal 
bovine serum (Sigma, USA) and antibiotics. AGS cells 
were transfected with following plasmids: pcDNA3.1, 
pcDNA3.1-PKD1 or pcDNA3.1-FLAG-PKD2. We used 
standard protocol of Ca-phosphate transfection 
followed by clone selection on G418 (0.6 mg/ml). 
After selection on G418 for 14 days, transfected cells 
were cloned and sublines that constitutively express 
PKD1 and PKD2 were obtained: AGS-PKD1, AGS-
PKD2 and AGS-pcDNA3.1.
To explore the characteristics of AGS transfectants 
we have used an array of standard in vitro assays, includ-
ing dye exclusion method with 0.4% trypan blue, MTT 
assay (colorimetric assay with 3-(4,5 Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide), cell migration 
scratch assay, Transwell and clonogenic assays [15–18].
The results of biological assays represent the 
mean + s.d. derived from at least three different ex-
periments. Statistical significance of differences was 
evaluated by Student’s t-test.
RESULTS AND DISCUSSION
In current study we have explored PKD1 and PKD2 ex-
pression on protein and mRNA levels in primary gastric 
cancer samples. To confirm our preliminary data on dif-
ferential level of PKD1/2 expression in gastric tumors 
tissues shown by immunohistochemistry [13], we have 
performed Western blot analysis and Q-PCR. Western 
blot analysis has shown both PKD1 (120 kDa) and 
PKD2 (105 kDa) expression in the majority of tumor sam-
ples. It should be noted that the low level of PKD1 expres-
sion was detected in low differentiated adenocarcinoma 
and signet-ring cell gastric cancer (Fig. 1, tracks 1–3, 
and data not shown). Altogether, in 6 out from 38 samples 
(15.8%) the level of PKD1 expression was much lower 
than PKD2. Moreover, in one case of adenogen cancer 
PKD1 expression was not detected on protein level.
To study the expression of PKD1 and PKD2 on mRNA 
level we applied Q-PCR analysis. In samples 2, 5, 7–9 of tu-
mors with poor prognosis, the level of PKD1 expression 
was considerably low in comparison with other tumor 
samples (Fig. 2). The highest level of PKD2 expression 
was shown for adenogen tumor (Fig. 2, sample 6) and 
low differentiated adenocarcinoma (Fig. 2, sample  2) that 
also had poor prognosis. At the same time in gastric tis-
sues surrounding both low and moderately differentiated 
adenocarcinomas (Fig. 2, samples 1 and 3) PKD1 and 
PKD2 were expressed on higher levels than in correspond-
ing tumors (Fig. 2, samples 2 and 4). It should be noted 
that in tumors with more favorable prognosis (moderately 
differentiated adenocarcinoma, cardioesophageal can-
cer and gastric adenoma, Fig. 2, samples 4, 10 and 11, 
respectively) the expression level of PKD1 mRNA was 
higher than in other cases.
1 2 3 4 5 6 7 8
9 10 11 12 13 14 15 16
150 kDa —
100 kDa —
50 kDa —
37 kDa —
150 kDa —
100 kDa —
50 kDa —
37 kDa —
— PKD1
— PKD2
— actin
— PKD1
— PKD2
— actin
Fig. 1. Western blot analysis of cancer cells from different histo-
logical variants of primary gastric cancer. 1 — low differentiated 
adenocarcinoma, 2 — normal gastric tissues surrounding low 
differentiated adenocarcinoma, 3 — signet-ring cell gastric carci-
noma, 4 — adenogen tumor, 5, 6, — gastric adenoma, 7, 8 — non 
differentiated cancer, 9, 13 — normal gastric tissues surrounding 
moderately differentiated adenocarcinoma, 10, 12, 14 — moder-
ately differentiated adenocarcinoma, 11 — carcinoid, 15 — cells 
lysate of НЕК293T-PKD2, 16 — cells lysate of НЕК293T-PKD1
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Fig. 2. Results of the Q-PCR on mRNA from tumor samples 
of different histological variants of primary gastric cancer. White 
columns — PKD1 expression ratio, black — the PKD2 expression 
ratio, both in comparison with PKD1 and PKD2 expression level 
in the sample of signet-ring cell gastric cancer, which demonstrated 
the lowest PKD1 and PKD2 expression levels. 1 — normal gastric 
tissues at low differentiated adenocarcinoma,  2 — low differenti-
ated adenocarcinoma, 3 — normal gastric tissues at moderately 
differentiated adenocarcinoma, 4 — moderately differentiated 
adenocarcinoma, 5 — non differentiated gastric cancer, 6 — adeno-
gen tumor, 7 — adenogen tumor (with metastasis), 8 — carcinoid 
cancer, 9 — signet-ring cell gastric cancer, 10 — cardioesophageal 
gastric cancer, 11 — gastric adenoma, Data on PKD2 expression 
level was normalized to expression of β2-microglobulin. *Exactly, the 
value on the level of PKD2 expression in sample 6 is significantly larger 
than the one shown in Fig.2 (sample 6: it is equal to 8012).
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Thus, we demonstrated the differential expression 
of PKD1 and PKD2 in various histological variants 
of primary gastric cancer and surrounding tissues 
on mRNA and protein levels.
PKD2 is the major serine/threonine protein ki-
nase of PKD family, which is expressed in human 
gastric adenocarcinoma cell line AGS. In AGS cells 
PKD2 is activated by gastrin and is a downstream 
target of PKCs [19]. PKD1 was not detectable in these 
cells on protein level (Fig. 3, a, track 4). To examine 
the role of PKD1 and PKD2 protein kinases in regula-
tion of gastric tumor cell biology we developed a AGS 
sublines expressing PKD1 or overexpressing PKD2. 
The expression levels of protein kinases PKD1 and 
PKD2 in constitutive transfectants was checked 
by Western blot (Fig. 3, a) using antibody against hu-
man PKCμ (Clone D-20, Santa Cruz, USA), which rec-
ognizes both PKD1 and PKD2. In our study, AGS cells 
were transfected with following plasmids: pcDNA3.1, 
pcDNA3.1-PKD1 or pcDNA3.1-FLAG-PKD2. Since 
FLAG peptide is about 7 kDa and PKD2 — 105 kDa the 
molecular weight of transfected PKD2 was expected 
to be 112 kDa (Fig. 3, a, tracks 1 and 2). PKD1 cDNA 
in pcDNA3.1 vector resulted in 120 kDa protein expres-
sion (Fig. 3, a, track 5).
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Fig. 3. The level of PKD1 and PKD2 expression in AGS sub-
lines. a. Western blot analysis of PKD1 and PKD2 expression 
in cell lysates. 1, 2 — AGS-PKD2 (two different colonies with 
over expression of protein kinase PKD2), 3 — AGS with empty 
pcDNA3.1 plasmid (transfection control), 4 — AGS, 5 — AGS-
PKD1. Western blot of actin expression served as a loading 
control (lower panel). b. Results of Q-PCR of PKD2 in AGS cell 
line and transfectants AGS-PKD1 and AGS-PKD2. The results 
of three independent experiments. Data on PKD2 expression 
level was normalized to expression of β2-microglobulin
Also we have checked mRNA levels of PKD1 and 
PKD2 in AGS-PKD1 and AGS-PKD2 sublines using 
Q-PCR analysis (Fig. 3, b). There was a prominent 
difference between the level of PKD2 mRNA in AGS-
PKD2 cells, which overexpress PKD2, when compared 
with AGS wild type cells (see Fig. 3, b). One of the 
clones tested expressed twice more of PKD2 coding 
mRNA, and other clone had 3.6 times more PKD2 cod-
ing mRNA than parental AGS cell line, reflecting the 
efficiency of transfection.
Also we have found that expression of PKD1 upon 
transfection in AGS cell line lead to the significant 
reduction of endogenous PKD2 mRNA and protein ex-
pression (see Fig. 3, b). Mechanisms and nature of this 
phenomenon require further study, but now we have 
shown in this study that expression of PKD1 kinase 
could influence the level of PKD2 expression.
Using Western blot analysis we have selected two 
sublines of each transfectants with different level of pro-
tein kinases PKD1 and PKD2 expression when com-
pared with parenteral AGS and AGS with empty plasmid 
(AGS-pcDNA3.1). These sublines (AGS-PKD2 and 
AGS-PKD1) were used to study the role of PKD1 and 
PKD2 isoforms in regulation of gastric tumor cell bio-
logy. These cell sublines were used for morphological 
study, comparative analysis in MTT and proliferation 
assays, and also tests for cell migration and survival.
Morphological examination of the transfectants 
AGS-PKD1 and AGS-PKD2 demonstrated that these 
cells acquired morphological features different from 
the parental AGS cells. AGS-PKD1 cells were of po-
lygonal shape, and increased in size in comparison 
with sublines with constitutive expression of PKD2, 
AGS-pcDNA3.1 and parental AGS cells (Fig. 4, a). 
It was observed that colonies of AGS-PKD1 cells had 
sufficiently more compact edge (Fig. 4, b), while colo-
nies of transfectant cells with constitutive expression 
of AGS-PKD2 had irregular edge. Moreover, AGS-
PKD2 cells were round-shaped (Fig. 4, c).
a b c
Fig. 4. The morphological differences of AGS sublines. a — con-
trol cell line AGS, b — transfectant AGS-PKD1, c — transfectant 
AGS-PKD2. x80
To explore the cell survival and proliferation 
activity the transfected cells were stained with 
0.4% trypan blue dye. Tested cells were cultured 
in 24-well plates in IMDM medium in concentration 
of 7х104 cell/ml/well in triplicates. After 24, 48 and 
72 h of cultivation the number of alive and dead cells 
was calculated. The transfection of AGS cell line with 
PKD1 or PKD2 did not significantly affect the survival 
of cells: the number of dead cells in each of the studied 
sublines was the same within 72 h of cultivation (from 
3.7% to 7.5%). At the same time we have revealed 
the significant differences in the number of alive 
cells for AGS-PKD1 and AGS-PKD2 sublines. After 
24 h of cultivation the number of AGS-PKD2 cells 
increased 4.6 times, while the number of control 
AGS cells — only 2.5 times. At the same time the rate 
of AGS-PKD1 subline proliferation was lower than 
of control AGS and AGS-pcDNA3.1 cells (Fig. 5, a, 
lower curve). The kinetics studies up to 72 hs showed 
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even more prominent difference. Taken together, 
AGS-PKD1 cell were characterized by slight inhibition 
of cell proliferation and AGS-PKD2 — with strongly 
enhanced proliferation rate, in comparison with AGS 
and AGS-pcDNA3.1 sublines.
We also applied MTT assay to evaluate cell prolif-
eration activity of transfected cells. With this approach 
we also observed the same difference between AGS-
PKD1 and AGS-PKD2 sublines and AGS parental cells 
in 24 hs of cultivation (Fig. 5, b). As shown on Fig. 5, 
b, AGS-PKD2 line had much higher proliferation 
activity than AGS-PKD1. Thus, PKD1 expression led 
to the inhibition of cell proliferation, and, in contrary, 
PKD2 overexpression resulted in the enhancement 
of cell proliferation.
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Fig. 5. Evaluation of proliferative activity of AGS, AGS-pcNDA3.1, 
AGS-PKD1 and AGS-PKD2 sublines. a — kinetics of cell number 
changes in cultures of AGS sublines. Results of three indepen-
dent experiments. b — MTT assay after 24 h of cultivation of AGS 
sublines. Results of three independent experiments
Since it is known that PKD1 kinase is involved 
in regulation of cell adhesion by phosphorylation 
of β-catenin, integrins and cortaktin [20, 21], we car-
ried out in vitro scratch and Transwell assays in order 
to access the migration properties of gastric cancer 
cell sublines that express PKD1 or PKD2. In in vitro 
scratch assay with cell cultures, expressing only 
PKD2 (AGS, AGS-pcDNA3.1 and AGS-PKD2), the 
migration of cells on the free surface of the plastic was 
observed already after 4 h. At the same time, for AGS-
PKD1 cells, migration was not registered for the same 
time period (Fig. 6, a). This trend was maintained for 
12, 24 and 48 h of observation. Even after 48 h in cul-
ture the free surface area of the scratch was only 
slightly decreased for AGS-PKD1 cells, while AGS-
PKD2 cells culture formed 100% confluent monolayer.
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Fig. 6. Evaluation of migration capacity of AGS cell sublines. a. 
In vitro scratch assay. A — AGS cell line at once after applying stripes 
(as control). B, C, D — all sublines after 24 h of incubation. B — AGS 
cell line, C — AGS-PKD1, D — AGS-PKD2. x 40. The arrow shows 
the initial size of scratch. (AGS-pcDNA3.1 — data not shown). 
b. Transwell assay. The representative fields on membrane after 
4 h of incubation. One of 5 evaluated fields for each cell subline. 
x40. Staining with crystal violet, cells are shown in blue, A — AGS, 
B — AGS-pcDNA3.1, C — AGS-PKD1, D — AGS-PKD2. c. Transwell 
assay. The level of cell migration activity estimated as a number 
of penetrated cells for 4 h in 5 microscopic fields at x40
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Further performed Transwell assay revealed that 
such behavior of transfectant cells could be explained 
by the different migration capacity of AGS transfec-
tants. The AGS-PKD2 transfectants had the highest 
level of migration activity. However, migration capacity 
of AGS-PKD1 cells was twice lower then of AGS and 
AGS-pcDNA3.1 control cells (Fig. 6, b, c).
To evaluate colony formation ability of AGS sub-
lines we have used clonogenic assay, which reflects 
the potential tumorogenic capacity of cells. After two 
weeks of cultivation AGS cells gave rise to 128 colo-
nies: 112 colonies with up to 20 cells/per colony and 
16 colonies — more than 20 cells/per colony. In cul-
tures of AGS-PKD1 transfectant all 72 colonies were 
less than 20 cells/colony. In the contrast, for AGS-
PKD2 transfectant we have detected 408 colonies 
including 176 colonies with more than 20 cells/colony. 
Numbers of colonies formed by control cultures 
transfected with empty plasmid were close to parental 
AGS line. Thus, PKD1 transfection decreases colony 
formation capacity of AGS, while PKD2 overexpres-
sion dramatically enhances colony formation (Fig. 7).
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Fig. 7. Clonogenic capacity of AGS sublines. Colony formation 
assay in soft agar. White columns — number of colonies with 
up to 20 cells, grey — number of colonies with more than 20 cells, 
black — all colonies. Results of three independent experiments
Our study provided new evidences of PKD1 and 
PKD2 differential expression in gastric cancer cells and 
their distinct roles in regulation of tumor cell biology. 
We have demonstrated that primary gastric tumors 
possess different levels of PKD1 and PKD2 expression 
on mRNA and protein levels that greatly complement 
the data on PKD1 mRNA expression previously obtained 
by Kim et al. [11]. We also found that low PKD1 expression 
levels (both on mRNA and protein level) are the feature 
of particular histological variants of gastric cancer: sig-
net-ring cell gastric carcinoma, undifferentiated gastric 
cancer, carcinoid and adenogen tumor with metastasis. 
To find the potential biological consequences 
of differential PKD1 and PKD2 expression in gastric 
cancer cells we have created experimental system based 
on AGS cells line. We have shown that the expression 
of PKD1 upon transfection in AGS cell line lead to the 
significant reduction of endogenous PKD2 mRNA ex-
pression. Various tests were performed, including MTT 
and proliferation assays, in vitro scratch, Transwell and 
clonogenic assays, which revealed clear difference 
in morphological features, proliferation, migration and 
colony formation of sublines overexpressing PKD2 or ex-
pressing PKD1. Overall, PKD1 transfection led to the 
inhibition of cell proliferation, migration and colony 
formation. Meanwhile, PKD2 overexpression enhanced 
cell proliferation, cellular migration and colony formation 
capacities. Thus, our data clearly show that both down-
regulation of PKD1 or upregulation of PKD2 expression 
may determine the behavior of tumor cells that resulted 
in invasive phenotype and in general poor prognosis.
Since differential expression of PKD1 and PKD2 pro-
tein kinases affects biological features of malignant 
cells in experimental system in vitro, heterogeneity 
in PKD1 and PKD2 expression of primary gastric tumor 
samples may influence the proliferative activity and 
migration capacity of tumor cells in vivo. Therefore, the 
studies of differential expression and activity of PKD1 and 
PKD2 in the context of tumor manifestation and prog-
nosis of the disease could be the perspective subject 
of translational research in oncology. This will contribute 
to the development of new approaches to differential 
diagnostics of tumor and target therapy, and also reveal 
prognostic factors for the prediction of clinical outcome.
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